KRRO
Korro Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.91
+4.95%Oct 5, 2026, 20:05 UTC
Korro Bio dosed the first cohort of participants in its Phase 1/2 ANCHOR clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy.
Source:Aug 6, 2026, 11:00 UTC
Korro Bio nominated KRRO-111 as a development candidate for the treatment of Alpha-1 Antitrypsin Deficiency.
Source:Aug 6, 2026, 11:00 UTC
Korro Bio received Orphan Drug Designation from the European Medicines Agency for KRRO-121 for patients with urea cycle disorders.
Source:Aug 6, 2026, 00:00 UTC
Korro Bio, Inc. exchanged 1,000,000 outstanding common shares for pre-funded warrants to purchase 1,000,000 new shares of common stock, with an exercise price of $0.001 per share, in a transaction with Venrock Healthcare Capital Partners entities on August 6, 2026.